• Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

    Source: Nasdaq GlobeNewswire / 10 Mar 2023 07:00:00   America/Chicago

    FORT LEE, NJ, March 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference.

    Event 35th Annual Roth Conference
    Date March 14, 2023
    Time 12:00 PM Pacific Time (3:00 PM Eastern Time)
    Format Fireside Chat
    Link https://wsw.com/webcast/roth46/nvct/1849405

    About Nuvectis Pharma

    Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is a clinical stage, oral small molecule currently in a Phase 1a study in patients with advanced solid tumors. NXP800 was granted Fast Track Designation by the United States Food and Drug Administration for the treatment of platinum-resistant, ARID1a-mutated, ovarian carcinoma. NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor with an IND pending submission.

    For more information, please visit www.nuvectis.com.

    Nuvectis Pharma Contact

    Ron Bentsur

    Chairman, Chief Executive Officer and President

    rbentsur@nuvectis.com

    Media Relations Contact

    Christopher M. Calabrese

    LifeSci Advisors

    Tel: 917-680-5608

    ccalabrese@lifesciadvisors.com  


    Primary Logo

Share on,